187 related articles for article (PubMed ID: 36142807)
21. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
[TBL] [Abstract][Full Text] [Related]
22. Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells.
Fang J; Gu L; Zhu N; Tang H; Alvarado CS; Zhou M
BMC Cancer; 2008 Mar; 8():69. PubMed ID: 18325115
[TBL] [Abstract][Full Text] [Related]
23. Morphine inhibits doxorubicin-induced reactive oxygen species generation and nuclear factor kappaB transcriptional activation in neuroblastoma SH-SY5Y cells.
Lin X; Li Q; Wang YJ; Ju YW; Chi ZQ; Wang MW; Liu JG
Biochem J; 2007 Sep; 406(2):215-21. PubMed ID: 17542780
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.
Smolensky D; Rathore K; Bourn J; Cekanova M
J Cell Biochem; 2017 Sep; 118(9):2615-2624. PubMed ID: 27649518
[TBL] [Abstract][Full Text] [Related]
25. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
26. Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.
Czaplinski S; Abhari BA; Torkov A; Seggewiß D; Hugle M; Fulda S
Oncotarget; 2015 Dec; 6(39):41522-34. PubMed ID: 26575016
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
28. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
29. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
[TBL] [Abstract][Full Text] [Related]
30. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
31. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
32. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
Kotchetkov R; Cinatl J; Blaheta R; Vogel JU; Karaskova J; Squire J; Hernáiz Driever P; Klingebiel T; Cinatl J
Int J Cancer; 2003 Mar; 104(1):36-43. PubMed ID: 12532417
[TBL] [Abstract][Full Text] [Related]
33. WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
Inge TH; Harris NL; Wu J; Azizkhan RG; Priebe W
J Surg Res; 2004 Oct; 121(2):187-96. PubMed ID: 15501458
[TBL] [Abstract][Full Text] [Related]
34. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells.
Emran MA; Rebbaa A; Mirkin BL
Cancer Lett; 2002 Aug; 182(1):53-9. PubMed ID: 12175523
[TBL] [Abstract][Full Text] [Related]
36. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
38. Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.
Treis D; Umapathy G; Fransson S; Guan J; Mendoza-García P; Siaw JT; Wessman S; Gordon Murkes L; Stenman JJE; Djos A; Elfman LHM; Johnsen JI; Hallberg B; Palmer RH; Martinsson T; Kogner P
JCO Precis Oncol; 2022 Jan; 6():e2100271. PubMed ID: 35085006
[No Abstract] [Full Text] [Related]
39. Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells.
Ganapathi R; Grabowski D; Hoeltge G; Neelon R
Biochem Pharmacol; 1990 Oct; 40(7):1657-62. PubMed ID: 2222519
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes.
Kim SY; Kim SJ; Kim BJ; Rah SY; Chung SM; Im MJ; Kim UH
Exp Mol Med; 2006 Oct; 38(5):535-45. PubMed ID: 17079870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]